Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

August 8, 2025

Q2’25 Psychedelic Lobbying Update • Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find • UK Moves Toward Easing Schedule I Research Restrictions But Keeps Industry at Arm’s Length • “Shell Games” and Whistleblowers: MassGOP Goes on Offensive Against Psychedelics Campaigners • Aussie University Seeks Public Comments on MDMA Clinical Practice Guideline • and more..

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling?

August 1, 2025

AbbVie Eyes Billion-Dollar Gilgamesh Acquisition • What Is Kyrsten Sinema Selling? • Compass ‘Encouraged’ by Germany’s Psilocybin Compassionate Use Program • Psychedelics Industry’s Input on EMA’s Draft Depression Guideline • National Survey Reveals Psychedelics Use Again Rises in US • FDA Moves to Ban Kratom Compound 7-OH • Compass Talks Accelerated Approval on Q2’25 Earnings Call • atai All-In on Psychedelics Following RL-007 Flop • UK Government Publishes Life Sciences Plan • NMDA or Opioid? Ketamine’s True Target Under Scrutiny • Budget, Dosing, and Paperwork Raised at OPS Listening Sessions • and more..

Germany Establishes EU’s First Psilocybin Compassionate Access Program

July 31, 2025

Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany’s model empowers clinicians to decide on patient eligibility without case-by-case regulatory approval and might succeed in having insurers cover much of the cost. Here, we speak with one of the program’s key architects, Gerhard Gründer.

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2)

July 29, 2025

In this second Dispatch from the inaugural Neurobiology of Psychedelics Gordon Research Conference, Dr. Alaina Jaster recaps Days 2 through 4, highlighting cutting-edge research on neuroplasticity, animal cognition, drug discovery, clinical studies, and altered states of consciousness. Featured speakers include Linda Simmler, David Erritzoe, Jennifer Mitchell, and many more.

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research

July 25, 2025

Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression • Spravato’s Monotherapy Success Puts Pressure on Psychedelics Developers • Longevity Crowd Hypes Psilocybin Study But Researchers Urge Caution • Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch? • 3 Years of Psychedelics Access via Canada’s Special Access Programme • The New Neuroplastogen Developer on the Block • and more…

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more